Back
Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting.
Journal article

Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting.

  • Favier G From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Gladman DD From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Merola JF From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Armstrong AW From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Boehncke WH From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Helliwell PS From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. p.helliwell@leeds.ac.uk.
Show more…
  • 2017-05-03
Published in:
  • The Journal of rheumatology. - 2017
GRAPPA
OUTCOMES
PSORIASIS
PSORIATIC ARTHRITIS
QUALITY OF CARE
Arthritis, Psoriatic
Benchmarking
Dermatology
Humans
Psoriasis
Quality of Health Care
Rheumatology
English Members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), in partnership with KPMG LLP (UK), conducted interviews at selected research centers around the globe to analyze the process of care in psoriasis and psoriatic arthritis (PsA): pre-diagnosis, referral and diagnosis, treatment, and followup. Ten major challenges emerged, many of which were universally recognized across centers; the top 4 included limited awareness of PsA among non-rheumatologists, a disparate approach to care, late referral and diagnosis, and an inadequate management of comorbidities.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/76652
Statistics
Document views: 26 File downloads: